5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry
L Tittl, S Marten, C Naue, J Beyer-Westendorf - Thrombosis Research, 2021 - Elsevier
Introduction Following successful phase-III trials, direct oral anticoagulants such as
rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF) …
rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF) …
5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry.
L Tittl, S Marten, C Naue… - Thrombosis Research, 2021 - europepmc.org
Materials and methods Prospective registries can provide such data but often limit follow-up
to short periods only. Extending our previously reported follow-up of 2.2 years in 1204 SPAF …
to short periods only. Extending our previously reported follow-up of 2.2 years in 1204 SPAF …
5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry
L Tittl, S Marten, C Naue… - Thrombosis …, 2021 - pubmed.ncbi.nlm.nih.gov
Introduction Following successful phase-III trials, direct oral anticoagulants such as
rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF) …
rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF) …
5-year outcomes from rivaroxaban therapy in atrial fibrillation: Results from the Dresden NOAC Registry
L Tittl, S Marten, C Naue… - Thrombosis …, 2021 - thrombosisresearch.com
Introduction Following successful phase-III trials, direct oral anticoagulants such as
rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF) …
rivaroxaban have largely replaced warfarin for stroke prevention in atrial fibrillation (SPAF) …